The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Discovery and clinical introduction of first-in-class imipridone ONC201
Open accessAbstract
// Joshua E. Allen 1 , C. Leah B. Kline 2 , Varun V. Prabhu 1 , Jessica Wagner 2 , Jo Ishizawa 3 , Neel Madhukar 4 , Avital Lev 2 , Marie Baumeister 2 , Lanlan Zhou 2 , Amriti Lulla 2 , Martin Stogniew 1 , Lee Schalop 1 , Cyril Benes 5,6 , Howard L. Kaufman 7 , Richard S. Pottorf 8 , B. Rao Nallaganchu 8 , Gary L. Olson 8 , Fahd Al-Mulla 9 , Madeleine Duvic 3 , Gen Sheng Wu 10 , David T. Dicker 2 , Mala K. Talekar 11 , Bora Lim 3 , Olivier Elemento 4 , Wolfgang Oster 1 , Joseph Bertino 7 , Keith Flaherty 5,6 , Michael L. Wang 3 , Gautam Borthakur 3 , Michael Andreeff 3 , Mark Stein 7 and Wafik S. El-Deiry 2 1 Oncoceutics, Inc., Philadelphia, PA, USA 2 Fox Chase Cancer Center, Philadelphia, PA, USA 3 University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Weill Cornell Medicine, New York, NY, USA 5 Massachusetts General Hospital, Boston, MA, USA 6 Harvard Medical School, Boston, MA, USA 7 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA 8 Provid Pharmaceuticals, Monmouth Junction, NJ, USA 9 Kuwait University Medical School, Kuwait 10 Karmanos Cancer Institute, Detroit, MI, USA 11 The Children’s Hospital of Philadelphia, Philadelphia, PA, USA Correspondence to: Wafik S. El-Deiry, email: // Keywords : ONC201, TIC10, integrated stress response, ATF4, DRD2 Received : August 23, 2016 Accepted : August 30, 2016 Published : September 01, 2016 Abstract ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC201 has anti-proliferative and pro-apoptotic effects against a broad range of tumor cells but not normal cells. The mechanism of action of ONC201 involves engagement of PERK-independent activation of the integrated stress response, leading to tumor upregulation of DR5 and dual Akt/ERK inactivation, and consequent Foxo3a activation leading to upregulation of the death ligand TRAIL. ONC201 is orally active with infrequent dosing in animals models, causes sustained pharmacodynamic effects, and is not genotoxic. The first-in-human clinical trial of ONC201 in advanced aggressive refractory solid tumors confirmed that ONC201 is exceptionally well-tolerated and established the recommended phase II dose of 625 mg administered orally every three weeks defined by drug exposure comparable to efficacious levels in preclinical models. Clinical trials are evaluating the single agent efficacy of ONC201 in multiple solid tumors and hematological malignancies and exploring alternative dosing regimens. In addition, chemical analogs that have shown promise in other oncology indications are in pre-clinical development. In summary, the imipridone family that comprises ONC201 and its chemical analogs represent a new class of anti-cancer therapy with a unique mechanism of action being translated in ongoing clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death
Han, J., Back, S. H., Hur, J., Lin, Y.-H., Gildersleeve, R., Shan, J., Yuan, C. L., Krokowski, D., Wang, S., Hatzoglou, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2738 · Cited by 1,691
The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression
B’chir, W., Maurin, A.-C., Carraro, V., Averous, J., Jousse, C., Muranishi, Y., Parry, L., Stepien, G., Fafournoux, P., & Bruhat, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt563 · Cited by 1,162
TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver
Du, K., Herzig, S., Kulkarni, R. N., & Montminy, M. (2003) · Science · doi:10.1126/science.1079817 · Cited by 842
Cited by
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
Ishizawa, J., Zarabi, S. F., Davis, R. E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St-Germain, J., Heese, L. E., Egan, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.014 · Cited by 349
Self-citation
Metadata
- Authors
- Allen, J. E., Kline, C. L. B., Prabhu, V. V., Wagner, J., Ishizawa, J., Madhukar, N., Lev, A., Baumeister, M., Zhou, L., Lulla, A., Stogniew, M., Schalop, L., Benes, C., Kaufman, H. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Al-Mulla, F., Duvic, M., Wu, G. S., Dicker, D. T., Talekar, M. K., Lim, B., Elemento, O., Oster, W., Bertino, J., Flaherty, K., Wang, M. L., Borthakur, G., Andreeff, M., Stein, M., & El-Deiry, W. S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-01
- Volume
- 7
- Issue
- 45
- Pages
- 74380-74392
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2514974106
- Cited by
- 164
- References
- 3
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and clinical introduction of first-in-class imipridone ONC201. https://app.cochat.ai/papers/10.18632/oncotarget.11814
- The paper
- Allen, J. E., Kline, C. L. B., Prabhu, V. V., Wagner, J., Ishizawa, J., Madhukar, N., Lev, A., Baumeister, M., Zhou, L., Lulla, A., Stogniew, M., Schalop, L., Benes, C., Kaufman, H. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Al-Mulla, F., Duvic, M., . . . El-Deiry, W. S. (2016). Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. https://doi.org/10.18632/oncotarget.11814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.